Cargando…

Pharmacodynamic biomarkers and differential effects of TNF‐ and GM‐CSF‐targeting biologics in rheumatoid arthritis

AIM: The aim of our study was to identify pharmacodynamic biomarkers and assess differential effects of tumor necrosis factor (TNF)‐ and non‐TNF‐targeting agents on rheumatoid arthritis (RA) patients with an inadequate response to anti‐TNF agents (anti‐TNF‐IR) in comparison with biologic‐naïve patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiang, Wang, Shiliang, Godwood, Alex, Close, David, Ryan, Patricia C., Roskos, Lorin K., White, Wendy I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587493/ https://www.ncbi.nlm.nih.gov/pubmed/30358109 http://dx.doi.org/10.1111/1756-185X.13395

Ejemplares similares

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes
por: Bystrom, Jonas, et al.
Publicado: (2017)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis
por: Greven, D E A, et al.
Publicado: (2015)

IL-1β and TNFα Promote Monocyte Viability through the Induction of GM-CSF Expression by Rheumatoid Arthritis Synovial Fibroblasts
por: Darrieutort-Laffite, Christelle, et al.
Publicado: (2014)

GM-CSF Expression and Macrophage Polarization in Joints of Undifferentiated Arthritis Patients Evolving to Rheumatoid Arthritis or Psoriatic Arthritis
por: Fuentelsaz-Romero, Sara, et al.
Publicado: (2021)

The efficacy and safety of targeting GM-CSF in arthritis
por: Bykerk, Vivian P
Publicado: (2020)

MLN51 and GM-CSF involvement in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis
por: Jang, Jinah, et al.
Publicado: (2006)

Th1 is the predominant helper T cell subset that produces GM-CSF in the joint of rheumatoid arthritis
por: Yamada, Hisakata, et al.
Publicado: (2017)

Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals
por: Vainshtein, Inna, et al.
Publicado: (2015)

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity
por: Pykhtina, Mariya, et al.
Publicado: (2021)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis
por: Reynolds, G, et al.
Publicado: (2016)

The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis
por: Vial, Gaelle, et al.
Publicado: (2021)

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development
por: Liang, Meina, et al.
Publicado: (2015)

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)

Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease
por: Cook, Andrew D, et al.
Publicado: (2001)

GM-CSF-Dependent Inflammatory Pathways
por: Hamilton, John A.
Publicado: (2019)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Development of Dendritic Cells from GM-CSF(-/-) Mice in vitro : GM-CSF Enhances Production and Survival of Cells
por: Ni, Keping, et al.
Publicado: (2001)

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2018)

NK cell–derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS
por: Louis, Cynthia, et al.
Publicado: (2020)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
por: Shiomi, Aoi, et al.
Publicado: (2015)

A Review of GM-CSF Therapy in Sepsis
por: Mathias, Brittany, et al.
Publicado: (2015)

GM-CSF: Orchestrating the Pulmonary Response to Infection
por: McCormick, Thomas S., et al.
Publicado: (2022)

Role of GM-CSF in lung balance and disease
por: Chen, Yingzi, et al.
Publicado: (2023)

Correction: NK cell–derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS
por: Louis, Cynthia, et al.
Publicado: (2020)

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
por: Bosteels, Cedric, et al.
Publicado: (2022)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

GM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity
por: Borriello, Francesco, et al.
Publicado: (2017)

ACSL1 Regulates TNFα-Induced GM-CSF Production by Breast Cancer MDA-MB-231 Cells
por: Thomas, Reeby, et al.
Publicado: (2019)

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
por: He, Kai, et al.
Publicado: (2022)

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
por: Burmester, Gerd R, et al.
Publicado: (2011)

Bone and TNF in rheumatoid arthritis: clinical implications
por: Manara, Maria, et al.
Publicado: (2015)

Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages in cats infected with feline infectious peritonitis virus contribute to the pathogenesis of granulomatous lesions
por: Takano, Tomomi, et al.
Publicado: (2009)

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
por: Neubauer, Sarah, et al.
Publicado: (2014)

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
por: Lopez-Rodriguez, Rosario, et al.
Publicado: (2018)

An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
por: Vugler, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h4ude2gddbddbo4943ee2jd6tf